Patient Leader Perspectives: Co-Design with ‘Patients from the Start’
These two accomplished patient leaders combined their experiences and perspectives to explain how industry can integrate “patients from the start.”
Posts
Migraine Patient-Reported Survey Data
New Health Union survey data show patients experience a very high number of symptoms and triggers, reinforcing that migraine is “more than just a headache.”
Chronic Migraine Headaches: Role of Smoking and Locus of Control
The findings of the present study imply that behavioral and psychological interventions can be beneficial for chronic migraines with external locus of control as those interventions can improve not only their psychological wellbeing but also their migraine outcomes.
CGRP Therapies for Migraine Effect on Quality of Life
Survey finds positive HCP relationships, negative quality of life for chronic migraine patients who currently use vs. never used CGRP therapies.
The headache of migraine management: Prevalence and efficacy of treatment type in a national migraine population
The findings of this study suggest that although complementary and integrative medicine (CIM) + conventional medicine (CM) was associated with a reduction in the number of migraine attacks per month, CIM alone was associated with the greatest reduction.
To journal or not to journal: Migraine journal use among 2015 Migraine in America cohort
Partnering with University of Colorado, this abstract was published at the Society of Behavioral Medicine Conference 2019 showcasing data from Health Union’s Migraine In America 2015 survey.
Childhood onset migraine and adult outcomes: A retrospective survey
Partnering with University of Chung-Ang and University of Colorado, this abstract showcases data from Health Union’s Migraine In America 2015 survey.
Survey Finds Migraine Patients Largely Unaware of Newly Available CGRP Medications
People living with migraine recently gained another significant tool to effectively manage their condition when the U.S. Food and Drug Administration approved the first treatment to target calcitonin-gene-related peptides (CGRP). However, only one-third of respondents of Migraine In America 2018, a national survey by Health Union, LLC of people impacted by the condition, are even aware of CGRP therapies.
Building Relationships vs. Publishing Content: Reflecting on the Renewed Interest In Migraine Disease
A new class of migraine drugs, called anti-CGRPs (calcitonin gene-related peptide) are expected to reinvigorate a market that has been largely dormant for some time. Four biopharma companies, Amgen, Teva, Lilly and Alder are entering the fray. Not surprisingly, the intense competition and pharma investment associated with this market dynamic has led traditional “eyeball driven” publishers, like WebMD, Everyday Health and others on a quest to offer substantially more migraine-related content in reaction to this market opportunity.
Migraine Takes a Major Toll on Work, School, and Social Life
A new Health Union survey of people currently diagnosed with migraine finds nearly three-quarters (73 percent) of respondents report their education and/or career had been affected by the condition. Among the 4,500 respondents to the Migraine In America online survey, migraine negatively affected all aspects of life, including their ability to work, attend school, and participate in social activities.
Podcast
Living with Migraine: Erica Carrasco
Erica Carrasco is the 2022 Social Health Award Winner for Creative Contributor. Erica uses her creativity to help advocate for migraine awareness, and she talks about how her experiences with hemiplegic migraine have influenced her work and advocacy efforts.
/
RSS Feed